Inhaled dry powder liposomal azithromycin for treatment of chronic lower respiratory tract infection
-
Published:2024-01
Issue:
Volume:
Page:123841
-
ISSN:0378-5173
-
Container-title:International Journal of Pharmaceutics
-
language:en
-
Short-container-title:International Journal of Pharmaceutics
Author:
Dallal Bashi Yahya H.,
Ali Ahlam,
Al Ayoub Yuosef,
Assi Khaled H.,
Mairs Rachel,
McCarthy Helen O.,
Tunney Michael M.,
Kett Vicky L.ORCID
Subject
Pharmaceutical Science
Reference85 articles.
1. Freeze-drying of nanoparticles: Formulation, process and storage considerations;Abdelwahed;Adv Drug Deliv Rev.,2006
2. Polyphosphate coated nanoparticles: Enzyme-activated charge-reversal gene delivery systems;Akkus-Dagdeviren;International Journal of Pharmaceutics.,2023
3. Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JAD, Jr., Criner GJ, et al. Azithromycin for prevention of exacerbations of COPD. The New England Journal of Medicine. 2011;365(8):689. PubMed PMID: edsgcl.267371340.
4. Alhajlan M, Alhariri M, Omri A. Efficacy and safety of liposomal clarithromycin and its effect on pseudomonas aeruginosa virulence factors. Antimicrob Agents Chemother. 2013;57(6):2694-704-704. doi: 10.1128/AAC.00235-13. PubMed PMID: edselc.2-52.0-84877855980.